Merck Steps Up As AiCuris’ First Development Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck partners with on AiCuris on letermovir and other antiviral candidates for human cytomegalovirus (HCMV), marking the first development deal for the German drug developer, spun out from Bayer in 2006.